Serotonin in Depression and Suicide

  • H. M. van Praag


Ever since the introduction of the antidepressants in the late fifties and the discovery that central monoamine (MA) metabolism is influenced by them, central MA, for example serotonin (5-hydroxytryptamine; 5-HT) has been studied in depression. What is the state of the art of 25 years later? Is 5-HT related to depression, or to certain features of depression, or is it not?


Suicide Attempt Suicidal Behavior Plasma Prolactin Suicide Victim Prolactin Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agren, H. (1980) Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid. Psychiat. Res., 3:225.CrossRefGoogle Scholar
  2. Agren, H. (1983) Life at risk:markers of suicidality in depression. Psychiat. Dev.,1:87.Google Scholar
  3. Asberg, M.; Traskman, L. and Thoren, P. (1976) Serotonin depressions biochemical subgroup within the affective disorders? Science,131:478–480.Google Scholar
  4. Baldessarini, R.J. (1983) Biomedical aspects of depression. American Academic Press.Google Scholar
  5. Banki, C.M. and Arato, M. (1983) Amine metabolites and neuroendocrine responses related to depression and suicide. J. Affect. Disord.,5:223.PubMedCrossRefGoogle Scholar
  6. Banki, C.M.; Molnar, G. and Vojnik, M. (1981) Cerebrospinal fluid amine metabolites, tryptophan and clinical parameters in depression:Psychopathological symptoms. J. Affect. Disord.,3:91.PubMedCrossRefGoogle Scholar
  7. Barbaccia, M.L.; Gandolfi, O.; Chaung, D. and Costa, E. (1983) Modulation of neuronal serotonin uptake by a putative endogenous ligand of imipramine recognition sites. Proc. Nat’l. Acad. Sci. USA.,80:5134–5138.CrossRefGoogle Scholar
  8. Bioulac, B.; Benezich, M.; Renaud, B.; Noel, B. and Roche, D. (1980) Serotonergic functions in the 47, XYZ syndrome. Biol. Psychiat.,15:917.PubMedGoogle Scholar
  9. Birkmayer, W. and Riederer, P. (1975) Biochemical post-mortem findings in depressed patients. J. -Neural. Transm.,37:95–109.PubMedCrossRefGoogle Scholar
  10. Briley, M.S.; Langer, S.Z.; Raisman, R.; Sechter, D. and Zarifian, E. (1980) Tritiated imipramine binding sites and decreased in platelets of untreated depressed patients. Science, 209:303–305.PubMedCrossRefGoogle Scholar
  11. Brown, G.L.; Ebert, M.E.; Goyer, P.F.; Jimerson, D.C.; Klein, W.J.; Bunney, W.E. and Goodwin, F.K. (1982) Aggression, suicide and serontonin:relationships to CSF amine metabolites. Am. J. Psychiat.,139:741.PubMedGoogle Scholar
  12. Brown, G.L.; Goodwin, F.K.; Ballenger, J.C.; Goyer, P.F. and Major, L.F. (1979) Aggression in humans correlates with cerebrospinal fluid metabolites. Psychiat. Res.,1:131.CrossRefGoogle Scholar
  13. Conte, H.R. and Plutchik, R. (1974) Personality and background characteristics of suicidal mental patients. J. Psychiat. Res.,10:181.PubMedCrossRefGoogle Scholar
  14. Freud, S. (1956) Mourning and melancholia. In: London, J.E., ed. Collected Papers, Hogarth Press.Google Scholar
  15. Gershon, E.S.; Cromer, M. and Klerman, G.L. (1968) Hostility and depression. Psychiat.,31:224.Google Scholar
  16. Hallert, C. and Sedvall, G. (1983) Improvement in central monoamine metabolism in adult coeliac patients starting a gluten- free diet. Psychol. Med.,13:267–271.PubMedCrossRefGoogle Scholar
  17. Heninger, G.R.; Charney, D.S. and Sternberg, D.E. (1984) Serotonergic function in depression. Arch. Gen. Psychiat.,41:398–402.PubMedCrossRefGoogle Scholar
  18. Hornykiewicz, O. (1981) Biochemical determinants of Parkinson’s disease. In: van Praag, H.M.; Lader, M.H.; Rafaelsen, O.J. and Sachar, E.J. eds. Handbook of Biological Psychiatry Part IV. (Marcel Dekker Inc. New York, Basel).Google Scholar
  19. Kato, Y.; Nakai, Y.; Imura, H.; Chihara, K.; and Ohgo, S. (1974) Effect of 5-Hydroxytryptophan (5-HTP) on plasma prolactin levels in man. J. Clin. Endoc. Metab.,38:695–697.CrossRefGoogle Scholar
  20. Lakke, J.P.W.F.; Korf, J.; van Praag, H.M. and Schut, T. (1972) Predictive value of the probenecid test for the effect of l-dopa therapy in Parkinson’s disease. Nature New Biology,236:208–209.PubMedGoogle Scholar
  21. Langer, S.Z. and Briley, M. (1981) High-affinity H-imipramine binding; a new biological tool for studies in depression. Trends Neurosci.,4:28.CrossRefGoogle Scholar
  22. Linnoila, M.; Virkkunen, M.; Scheinin, M.; Nuutila, A.; Rimon, R,. and Goodwin, F. K. (1983) Low cerebrospinal fluid 5-Hydroxy- indoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci.,33:2609–2614.PubMedCrossRefGoogle Scholar
  23. Lloyd, K.J.; Farley, I.J.; Deck, J.H.N, and Hornykiewicz, O. (1974) Serotonin and 5-Hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients. Adv. Biochem. Psychopharmacol.,11:387–397.PubMedGoogle Scholar
  24. Mayeux, R.; Stern, Y.; Cote, L. and Williams, J.B.W. (In press, 1984) Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology.Google Scholar
  25. Mayeux, R.; Stern, Y.; Rosen, J. and Leventhal, J. (1981) Depression, intellectual impairment and Parkinson’s disease. Neurology 31:645–650.PubMedCrossRefGoogle Scholar
  26. McBride, P.A.; Mann, J.J.; McEwen, B. and Biegon, A. (1983) Characterization of serotonin binding sites on human platelets. Life Sci.,33:2033.PubMedCrossRefGoogle Scholar
  27. Meltzer, H.Y.; Tricou, B.J.; Robertson, A. and Lowry, M. (1983) Hormone response to 5-HTP. Psychiat. Res.,10:151.CrossRefGoogle Scholar
  28. Meyerson, L.R.; Wennogle, L.P.; Abel, M.S.; Coupet, J.; Lippa, A.S.; Rau, C.E. and Beer, B. (1982) Human brain receptor alterations in suicide victims. Pharmacol. Biochem. Behav.,17:159–163.PubMedCrossRefGoogle Scholar
  29. Mindham, R.H.S. (1970) Psychiatric syndromes in parkinsonism. J. Neurol. Neurosurg. Psychiat.,30:188–191.CrossRefGoogle Scholar
  30. Møller, S.E. and Kirk, L. (1981) Decreased tryptophan availability in endogenous depression caused by disturbed plasma leucine clearance. Prog. Neuro Psychopharmacol.,5:277–279.CrossRefGoogle Scholar
  31. Møller, S.E.; Kirk, L. and Fremming, K.H. (1976) Plasma amino acids as an index for subgroup in manic depressive psychosis: correlation to effect of tryptophan. Psychopharmacologia, 49:205–213.CrossRefGoogle Scholar
  32. Møller, S.E.; Kirk, L. and Honore, P. (1980) Relationship between plasma ratio of tryptophan to competing amino acids and the response to l-tryptophan treatment in endogenously depressed patients. J. Affect. Disord.,2:47–50.PubMedCrossRefGoogle Scholar
  33. Montgomery, S.A. and Montgomery, D. (1982) Pharmacological prevention of suicidal behavior. J. Affect. Disord.,4:291.PubMedCrossRefGoogle Scholar
  34. Morand, C.; Young, S.N. and Ervin, F. R. (1983) Clinical response of aggressive schizophrenics to oral tryptophan. Biol. Psychiat., 18:575–578.PubMedGoogle Scholar
  35. Perry, E.K.; Marshall, E.F.; Blessed, G.; Tomlinson, B.E. and Perry, R.H. (1983) Decreased imipramine binding in the brains of patients with depressive illness. Brit. J. Psychiat.,142:188–192.PubMedCrossRefGoogle Scholar
  36. Puhringe, W.; Wirz-Justice, A.; Graw, P.; Lacoste, V. and Gastpar, M. (1976) Intravenous £-5-hydroxytryptophan in normal subjects: an interdisciplinary precursor loading study. I. Implication of reproducible mood elevation. Pharmakopsychiat.,9:260–268.CrossRefGoogle Scholar
  37. Rhavi, M.; Paul, S.M.; Skolnick, P. and Goodwin, F.K. (1980) Demonstration of specific high affinity binding sites for 3H-imipramine in human brain. Life Sci.,26:2273–2279.CrossRefGoogle Scholar
  38. Roos, B.E. and Sjostrom, R. (1969) 5-Hydroxyindoleacetic acid and homovanillic acid levels in the cerebrospinal fluid after probenecid application in patients with manic-depressive psychosis. J. Clin, Pharmacol.,1:153–155.CrossRefGoogle Scholar
  39. Rotman, A. (1983) Blood platelets in psychopharmacological research. Prog. Neuropsychopharmacol. and Biol. Psychiat., 7:135–151.CrossRefGoogle Scholar
  40. Roy-Byrne, P.; Post, R.M.; Rubinow, D.R.; Linnoila, M.; Savard, R. and Davis, D. (1983) CSF 5-HIAA and personal and family history of suicide in affectively ill patients:a negative study. Psychiat. Res.,10:263–274.CrossRefGoogle Scholar
  41. Shopsin, B.; Gershon, S.; Goldstein, S.; Friedman, M. and Wilk, S. (1974) Use of synthesis inhibition in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol. Bull.,10:52.PubMedGoogle Scholar
  42. Siever, L.J.; Murphy, D.L.; Slater, S.; de la Vega, E. and Lipper, S. (1984) Plasma prolactin changes following fenfluramine in depressed patients compared to controls:an evaluation of central serotonergic responsivity in depression. Life Sci.,34: 1029–1039.PubMedCrossRefGoogle Scholar
  43. Stanley, M. and Mann, J.J. (1983) Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet,1:214–216.PubMedCrossRefGoogle Scholar
  44. Stanley, M.; Virgilio, J. and Gershon, S. (1982) Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science,216:1337–1339.PubMedCrossRefGoogle Scholar
  45. Tamarkin, N.R.; Goodwin, F.K. and Axelrod, J. (1970) Rapid elevation of biogenic amine metabolites in human CSF following probenecid. Life Sci.,9:1397–1408.CrossRefGoogle Scholar
  46. Thai, L.J.; Sharpless, N.S.; Wolfson, L. and Katzman, R. (1980) Treatment of myoclonus with ¿-5-hydroxytryptophan and carbidopa. Clinical, electrophysiological and biochemical observation. Ann. Neurol.,7:570–576.CrossRefGoogle Scholar
  47. Thomson, J.; Rankin, H.; Ashcroft, G.W.; Yates, C.M.; McQueen, J.K. and Cummings, S.W. (1982) The treatment of depression in general practice:a comparison of l-tryptophan, amitriptyline, and a combination of l-trytophan and amitriptyline with placebo. Psychol. Med.,12:741–751.PubMedCrossRefGoogle Scholar
  48. Traskman, L.; Asberg, M.; Berulsson, L. and Sjostrand, L. (1981) Monoamine metabolites in CSF and suicidal behavior. Arch. Gen. Psychiat., 38:631–636.PubMedCrossRefGoogle Scholar
  49. Trimble, M.; Chadwick, D.; Reynolds, E. and Marsden, C.D. (1975) £-5-hydroxytryptophan and mood. Lancet, I:583.CrossRefGoogle Scholar
  50. Valzelli, L. (1981) Psychobiology of aggression and violence. Raven Press, New York.Google Scholar
  51. van Praag, H.M. (In press, 1984a) Studies in the mechanism of action of serotonin precursors in depression. Psychopharm. Bull.Google Scholar
  52. van Praag, H.M. (In press, 1984b) Brain serotonin and human (autoaggression). In: Usdin, E., Neuroscience Research Symposium, eds. Bunney, W.E. and Barchas, J.D.Google Scholar
  53. van Praag, H.M. (1983) In search of the action mechanism of antidepressants. 5-HTP/tyrosine mixtures in depression. Neuropharmacol.,22:433–440.CrossRefGoogle Scholar
  54. van Praag, H.M. (1983) CSF 5-HIAA and suicide in non-depressed schizophrenics. Lancet,11:977–978.CrossRefGoogle Scholar
  55. van Praag, H.M. (1982) Neurotransmitters and CSN disease: Depression. Lancet,11:1259–1264.Google Scholar
  56. van Praag, H.M. (1982) Depression, suicide and the metabolism of serotonin in the brain. J. Affect. Disord.,4:275–290.PubMedCrossRefGoogle Scholar
  57. van Praag, H.M. (1981) Management of depression with serotonin precursors. Biol. Psychiat.,16:291–310.PubMedGoogle Scholar
  58. van Praag, H.M. (1978) Psychotropic drugs. A guide for the practitioner. Brunner/Mazel, New York.Google Scholar
  59. van Praag, H.M. (1978) Amine hypotheses of affective disorders. In: Iversen, L.L.; Iverson, S.D. and Snyder, S.H., eds. Handbook of Psychopharmacology:Vol 13. Biology of mood and anti-anxiety drugs. Plenum Press, New York, Amsterdam, London.Google Scholar
  60. van Praag, H.M. (1977) Depression and schizophrenia. A contribution on their chemical pathologies. Spectrum Publication, New York.Google Scholar
  61. van Praag, H.M. and de Haan, S. (1980) Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiat. Res.,3:75–83.CrossRefGoogle Scholar
  62. van Praag, H.M.; Korf, J.; Dols, L.C.W. and Schut, T. (1972) A pilot study of the predictive value of the probenecid test in application of 5-hydroxytryptophan as antidepressant. Psycho- pharmacologia,25:14–21.CrossRefGoogle Scholar
  63. van Praag, H.M.; Korf, J; Lakke, J. P. W. F. and Schut, T. (1975) Dopamine metabolism in depressions, psychoses and parkinson’s disease:The problem of the specificity of biological variables in behavior disorders. Psychol. Med.,5:138–146.PubMedCrossRefGoogle Scholar
  64. van Praag, H.M.; Korf, J. and Puite, J. (1970) 5-Hydroxyindolea- cetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid. Nature,225:1259–1260.PubMedCrossRefGoogle Scholar
  65. van Praag, H.M. and Plutchik, R. (In Press) Depression-type and depression-severity in relation to risk of violent suicide attempt. Psychiat. Res.Google Scholar
  66. van Praag, H.M. and Westenberg, H.G.M. (1983) The treatment of depressions with £-5-hydroxytryptophan. In: Mendlewicz, J. and van Praag, H. M. eds. Management of Depression With Monoamine Precursors. S. Karger/Basel.Google Scholar
  67. van Praag, H.M.; Westenberg, H.G.M.; Thyssen, J.H.H. and de Jong, J.T.V.M. (1984) Hormone response to 5-HTP:A reply. Psychiat. Res.,11:79.CrossRefGoogle Scholar
  68. van Woert, M.H.; Rosenbaum, D.; Howieson, J. and Bowers, M.B. (1977) Long-term therapy and myoclonus and other neurological disorders with l-5-hydroxytryptophan and carbidopa. N. Engl. J. Med.,296:70–75.PubMedCrossRefGoogle Scholar
  69. Weissman, M.; Fox, K. and Klerman, J. L. (1973) Hostility and depression associated with suicide attempts. Am. J. Psychiat., 130:450.Google Scholar
  70. Westenberg, H.G.M.; van Praag, H.M.; de Jong, J.T.V.M. and Thyssen, J.H.H. (1982) Postsynaptic serotonergic activity in depressive patients evaluation of the neuroendocrine strategy. Psychiat. Res.,7:361–371.CrossRefGoogle Scholar
  71. Wood, P.L.; Suranyi-Cadotte, B.E.; Nair, N.P.V.; LaFaille, F. and Schwartz, G. (1983) Lack of association between [3H] ímipramine binding sites and uptake of serotonin in control, depressed and schizophrenic patients. Neuropharmacol.,22:1211–1214.CrossRefGoogle Scholar
  72. Wurtman, R. J. (1982) Nutrients that modify brain function. Sci. Am., 246:42.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • H. M. van Praag
    • 1
  1. 1.Department of PsychiatryAlbert Einstein College of Medicine/Montefiore Medical CenterBronxUSA

Personalised recommendations